COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production

API Major, Lasa Supergenerics and Institute of Chemical Technology had come together in the month of March 2020 in effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

Commenting on the development, Dr Omkar Herlekar, Chairman- Lasa Supergenerics Limited, said Efforts over the last few months has brought success and we are looking to manufacture close to 10,000 doses to begin with and in the meanwhile also apply for the drug licence with competent authorities and continue to seek strategic private investments or Government aid. Our move into human steroid API is in line with the organisations inherent strengths and objectives to diversify.

Commenting on the antivirals successful synthesis, Prof. Vikas N Telvekar, ICT, Mumbai, said we are happy to share with you that the Favipiravir molecule has been successfully synthesized in the ICT laboratory on a lab scale and further pilot plan scale up is required."

Recently in its Q4 results, the company reported a healthy increase in its PAT to Rs 3.63 cr for FY20, as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal.

Shares of Lasa Supergenerics Ltd was last trading in BSE at Rs.40.15 as compared to the previous close of Rs. 38.05. The total number of shares traded during the day was 10119 in over 91 trades.

The stock hit an intraday high of Rs. 40.55 and intraday low of 39.3. The net turnover during the day was Rs. 403790.

Source : Equity Bulls

Keywords